Licensing deal
US biotech Genencor International Inc, a subsidiary of Danisco, has completed a commercial licence agreement with German spin-out Gene Bridges to use its Red/ET Recombineering technology.
Gene Bridges, a spin-out from the European Molecular Biology Laboratory, has developed a technology which modifies E. coli–compatible DNA target molecules via a homologous recombination process. The technology allows every type of DNA modification possible in a short time frame, irrespective of DNA size and presence of restriction sites, says the company.
The company, co-directed by A. Francis Stewart, acquired the rights to exclusive commercialisation of Red/ET Recombineering in 2000. The European Molecular Biology Laboratory, where Stewart developed the technology, remains a major shareholder.
The licence agreement will allow Genencor to genetically engineer recombinant micro-organisms for industrial applications. Gary Stevens, CEO of Gene Bridges GmbH, said: “We are very pleased to add Danisco to the list of major industrial biotechnology companies using Red/ET. Recombineering is the technology of choice in DNA engineering and is used worldwide in industry and academia.”
Gene Bridges provides Red/ET technology to academia and industries worldwide through licensing, service provision and commercialisation of kits.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.